Research

Clinical research

Clinical trials and registries

Clinical research follows directly from the questions met in medical practice. It aims to characterise diseases better, to identify their prognostic determinants and their biomarkers, and to assess new treatment strategies.

The studies listed here are the clinical trials, prospective cohorts and registries coordinated or co-coordinated within the department of internal medicine and clinical immunology at Saint-Antoine Hospital, together with French and international teams.

The main programmes concern reproductive immunology, autoimmune and autoinflammatory diseases, myeloid malignancies associated with inflammatory manifestations, and the study of the relations between clonal haematopoiesis and immune dysregulation.

An ongoing trial has no result, and a preprint is not a publication: both are labelled as such.

Trials, cohorts and registries in which Prof. Arsène Mekinian takes part

The “declared role” column reports the role stated by Prof. Arsène Mekinian. Public registries name only the sponsor and, depending on the study, a principal investigator, who is not always the coordinator: where the registry names someone else, the row says so.

Study	Field	Public identifier	Declared role	Status
FALCO	Unexplained recurrent miscarriage National prospective cohort Sponsor: AP-HP. Status recorded on ClinicalTrials.gov on 8 September 2026, record updated on 19 December 2025. Publication: Human Reproduction, 2024.	NCT05557201	Coordinating investigator	Recruiting
FaCIL-2	Recurrent early miscarriage Low-dose interleukin-2 Trial closed on 20 March 2024. The public registry names David Klatzmann as principal investigator and Arsène Mekinian as study director for the Saint-Antoine site. Results are available as a medRxiv preprint only: not yet peer-reviewed.	NCT03970954	Coordinating investigator	Completed
CERTIFY	Recurrent implantation failure Certolizumab versus placebo Sponsor: AP-HP. The ClinicalTrials.gov record has not been updated since 11 December 2023. The coordinating role remains to be confirmed: an AP-HP page names another coordinator.	NCT05930613	Coordinating investigator	Recruiting
HYDROSAPL	Obstetric antiphospholipid syndrome Hydroxychloroquine versus placebo Study withdrawn: no participant included. Status recorded on ClinicalTrials.gov on 8 September 2026, record updated on 6 April 2026. Not to be confused with the acronym “HYDROAPS”, which is incorrect.	NCT04275778	Coordinating investigator	Withdrawn
CHIS	Clonal haematopoiesis and immune manifestations Ambispective cohort Clonal Hematopoiesis of Immunological Significance. Sponsor: AP-HP, with Sorbonne Université, Inserm and the MINHEMON club. Estimated start in April 2026, record updated on 23 March 2026.	NCT05969821	Principal investigator	Not yet recruiting
PAXIS	VEXAS syndrome Pacritinib, phase II Protocol PAC601. A second pacritinib trial in VEXAS syndrome exists (NCT06538181): the two are not to be confused.	NCT06782373	Coordinating investigator for Saint-Antoine	Active, not recruiting
SCLEROMICROBIO	Systemic sclerosis Gut microbiota Sponsor: AP-HP. ClinicalTrials.gov lists the record with unknown status, for want of an update by the sponsor.	NCT04791280	Coordinating investigator	Status not updated
TOCITAKA	Takayasu arteritis First-line tocilizumab EudraCT 2013-005039-26. He is first author of the 2020 publication (Arthritis Res Ther, PMID 32943098). The public registry names Olivier Fain as principal investigator.	NCT02101333	Coordinating investigator	Completed
TOCIALLON	Giant cell arteritis with ophthalmic involvement Tocilizumab Sponsor as stated: Hôpital des Quinze-Vingts. No record found on ClinicalTrials.gov on 8 September 2026. Identifier to be obtained before publication.	no public identifier found	Coordinating investigator	To be verified
AZA-SAID	Myelodysplastic syndromes with autoimmune manifestations Azacitidine, phase II Sponsor: Groupe francophone des myélodysplasies (GFM).	NCT02985190	Coordinating investigator	Completed
TOGIAC	Giant cell arteritis with cerebrovascular involvement Tocilizumab plus steroids versus placebo, phase III EudraCT 2020-000080-23. Sponsor: AP-HP, with Roche. Inclusions closed on 29 January 2025. The public registry names Sonia Alamowitch as principal investigator.	NCT04888221	Coordinating investigator	Active, not recruiting

Participation. This site does not recruit. Taking part in a study is discussed with the physician in charge of follow-up, who refers the file to the investigating centre where the situation calls for it. No registration, no appointment request and no medical record is handled through this site.

Multidisciplinary team meetings and expert opinions

The department coordinates several national multidisciplinary team meetings (RCP) and national expert schemes, through which physicians can obtain a collegial opinion on complex diagnostic or therapeutic situations.

The national “Infertility” meeting of the FAI²R rare-disease network is devoted to unexplained repeated pregnancy failure, recurrent miscarriage and placental disorders such as intervillositis, which call for multidisciplinary expertise. Arsène Mekinian states that he coordinates it; the network publishes the meeting and lists him among its experts, without publicly naming a coordinator.

The national MINHEMON meeting of the FAI²R network is devoted to the autoimmune and inflammatory manifestations associated with myeloid malignancies, in particular in myelodysplastic syndromes and clonal disorders.

These schemes are meant for physicians caring for a patient who wish to seek specialist expertise or a multidisciplinary discussion. They complement the specialist consultation and allow, depending on the situation, a diagnostic or therapeutic discussion, or referral to an expert centre or a research protocol.